StockNews.AI
PFE
StockNews.AI
14 days

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

1. Pfizer raised its 2025 EPS guidance after strong Q2 results. 2. The CEO highlighted progress in R&D and commercial performance.

Earnings
+2.02%Current Return
VS
+0.22%S&P 500
$23.5308/05 06:54 AM EDTEvent Start
$24.00508/06 01:36 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Pfizer's ability to raise EPS guidance suggests a strong financial outlook, historically correlating with positive stock performance. For instance, similar adjustments in 2021 led to significant stock price increases.

How important is it?

The article discusses key financial metrics and forward guidance, which are crucial for investors' assessments of PFE's growth potential and stability.

Why Short Term?

Immediate market reactions to earnings and guidance often influence stock prices in the short term, as seen following quarterly reports.

Related Companies

ABTMRKJNJ
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company.

Related News